This dataset compiles around 1,500 pharmaceutical products widely marketed globally but not yet present in Kenya, highlighting significant gaps in the local pharmaceutical landscape. It spans diverse classes — from biosimilars, biologics, and immune therapies to antibiotics, analgesics, and metabolic agents — with many either already off-patent or nearing patent expiry, and largely lacking local competitors. This positions the list as a clear strategic roadmap for Kenyan manufacturers and distributors to identify under-served therapeutic areas, accelerate PPB registrations, and secure early market leadership in high-value segments.

Additionally, the data underscores a notable emphasis on combination therapies, ranging from simple dual agents to complex multi-mechanism stacks that are commonplace in markets like India, Bangladesh, Pakistan, and Egypt but underrepresented in Kenya. Coupled with the timeline insights from patent expiries and the consistently low local competitive presence, this provides a blueprint for local players to strategically prioritize formulations that can address existing treatment gaps while capturing substantial commercial opportunity.